DSIP is for laboratory research use only and is not approved for human or clinical use
Lixisenatide therapy in older patients with type 2 diabetes inadequately controlled on their current antidiabetic treatment: the getgoal-o randomized trial
While more studies in psychiatric populations are needed, obesity and antipsychotic-induced obesity are more alike than different, and it is likely that other GLP-1 RAs will work in this population as well
Overuse may cause mild digestive discomfort
Jae Hyung Park (Sungkyunkwan University, Republic of Korea) and his colleagues have developed a tumor-targeted, bioreducible nanoparticle system that can deliver cytotoxic anticancer drugs to tumor tissues and release the drugs inside cancer cells in response to the intracellular molecule glutathione
PlexusDx Personalized Approach to GLP-1 Safety PlexusDx compounds semaglutide and tirzepatide through licensed 503A pharmacies, enabling customized dosing protocols not available through commercial products like Wegovy or Mounjaro